The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer
Abstract
Graphical abstract Figure. No caption available. Abstract Protein‐based micelles have shown significant potential for tumor‐targeted delivery of anti‐cancer drugs. In this light, self‐assembled nanocarriers based on GRAS (Generally recognized as safe) amphiphilic protein co‐polymers were synthesized via carbodiimide coupling reaction. The new nano‐platform is composed of the following key components: (i) hydrophobic zein core to encapsulate the hydrophobic drugs rapamycin (RAP) and wogonin (WOG) with high encapsulation efficiency, (ii) hydrophilic lactoferrin (Lf) corona to enhance the tumor targeting, and prolong systemic circulation of the nanocarriers, and (iii) glutaraldehyde (GLA)‐crosslinking to reduce the particle size and improve micellar stability. Zein‐Lf micelles showed relatively rapid release of WOG followed by slower diffusion of RAP from zein core. This sequential release may aid in efflux pump inhibition by WOG thus sensitizing tumor cells to RAP action. Interestingly, these micelles showed good hemocompatibility as well as enhanced serum stability owing to the brush‐like architecture of Lf shell. Moreover, this combined nano‐delivery system maximized synergistic cytotoxicity of RAP and WOG in terms of tumor inhibition in MCF‐7 breast cancer cells and Ehrlich ascites tumor animal model as a result of enhanced active targeting. Collectively, GLA‐crosslinked zein‐Lf micelles hold great promise for combined RAP/WOG delivery to breast cancer with reduced drug dose, minimized side effects and maximized anti‐tumor efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Block copolymer micelles: preparation, characterization and application in drug delivery
Gaucher, G., Dufresne, M.-H., Sant, V. P., Kang, N., Maysinger, D., & Leroux, J.-C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.034 · Cited by 1,498 · cited 1×
“Many amphiphilic materials are known to form micelles including surfactants and synthetic block co-polymers [19].”
BackgroundRapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Liu, J., Xiao, Y., & Allen, C. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10533 · Cited by 358 · cited 1×
“951%, respectively due to high degree of compatibility between drugs and the hydrophobic core-forming block of the micelles [49].”
Background
Cited by
Protein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 619
Li, B., Shao, H., Gao, L., Li, H., Sheng, H., & Zhu, L. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2094498 · Cited by 289
Metadata
- Authors
- Sabra, S. A., Elzoghby, A. O., Sheweita, S. A., Haroun, M., Helmy, M. W., Eldemellawy, M. A., Xia, Y., Goodale, D., Allan, A. L., & Rohani, S.
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 128
- Pages
- 156-169
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W2802912669
- Cited by
- 170
- References
- 5
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.